Related Experiment Video
Updated: Jun 12, 2026
07:20
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Advances in platinum chemotherapeutics
Benjamin W Harper1, Anwen M Krause-Heuer, Maxine P Grant
1Nanoscale Organisation and Dynamics Group, College of Health and Science, University of Western Sydney, Locked Bag 1797, Penrith South DC, NSW, 1797 Australia.
Chemistry (Weinheim an Der Bergstrasse, Germany)
|June 10, 2010
Summary
Researchers are developing new platinum-based chemotherapy drugs to improve cancer treatment. These advancements focus on better drug targeting and delivery systems to minimize side effects associated with cisplatin and its analogues.
Area of Science:
- Oncology
- Medicinal Chemistry
- Nanotechnology
Background:
- Platinum(II)-based anticancer agents like cisplatin, carboplatin, and oxaliplatin are standard treatments but have significant side effects.
- Current research aims to overcome these limitations through innovative drug development strategies.
Purpose of the Study:
- To review recent advances in platinum-based chemotherapeutics.
- To highlight technologies enhancing drug targeting and delivery for improved efficacy and reduced toxicity.
Main Methods:
- Exploration of cancer-specific targeting via biologically significant molecules.
- Investigation of platinum(IV) prodrugs for intracellular activation to cisplatin.
- Review of drug delivery systems including liposomes, dendrimers, polymers, and nanotubes.
Main Results:
- Targeting strategies show promise for concentrating platinum complexes in cancerous tissues.
- Platinum(IV) administration enables controlled release of active platinum species within cells.
- Various drug delivery platforms demonstrate potential for effective platinum compound delivery.
Conclusions:
- Advances in platinum chemotherapeutics focus on leveraging cisplatin's cytotoxicity while improving targeting.
- Novel drug delivery and administration methods are crucial for reducing side effects and enhancing patient outcomes.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...